C2 PHARMA
Katrien Oosterom is a Senior Vice President of Regulatory Affairs with a wealth of experience in pharmaceutical, healthcare, and quality control roles spanning over two decades. Oosterom has held various titles such as Manager Quality Control/Qualified Person and Regulatory Affairs Scientist, where Katrien has been responsible for writing regulatory submissions and communicating with Health Authorities globally. With a background in Clinical Information Analysis and Quality Assurance, Oosterom brings a broad skill set to their current role at C² PHARMA.
This person is not in any offices
C2 PHARMA
C2 PHARMA (http://www.c2pharma.com) is a pharmaceutical group established in 2014. It manufactures and distributes active pharmaceutical ingredients (APls) and complex chemical compounds obtained from natural and synthetic origins. The current API product portfolio includes cyclopentolate, atropine, digoxin, homatropine, pilocarpine, brimonidine, latanoprost, bimatoprost and reaches more than 100 pharmaceutical companies across the United States, Western and Eastern Europe, South America, Asia, Middle-East and Africa. C² PHARMA also offers customized cold-chain logistics solutions through its specialized affiliate Logistics4Pharma (http://www.logistics4pharma.com) as well as R&D-scale synthesis services of complex organic molecules and impurities through its affiliate ASM Research Chemicals (http://www.asm-research-chemicals.de). C² PHARMA is a key sponsor of the “Partnership for a Better World” program that ensures a sustainable, traceable & fair-trade harvesting and sourcing of phytochemical and botanicals used for pharmaceutical APIs such as Pilocarpine. The program sustains of more than 1,000 families and contributes to the preservation of the Brazilian biodiversity. #c2Pharma; #C²Pharma; #c2 Pharma; #C² Pharma; #Centroflora CMS